These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 18997742)

  • 41. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov.
    Law MR; Kawasumi Y; Morgan SG
    Health Aff (Millwood); 2011 Dec; 30(12):2338-45. PubMed ID: 22147862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDA regulatory compliance reconsidered.
    Tobias C
    Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
    [No Abstract]   [Full Text] [Related]  

  • 43. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
    Rivera DR; Hartzema AG
    Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Illegal drug trade discovered in Bavaria. How can we protect ourselves from drug falsification?].
    Schweim HG
    MMW Fortschr Med; 2005 Sep; 147(38):11. PubMed ID: 16218221
    [No Abstract]   [Full Text] [Related]  

  • 45. Drug makers are still giving gifts to doctors, F.D.A. officials tell senators.
    Harris G
    N Y Times Web; 2005 Mar; ():A15. PubMed ID: 15948332
    [No Abstract]   [Full Text] [Related]  

  • 46. Black box warnings-implications in practice.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(6):402-9. PubMed ID: 19064138
    [No Abstract]   [Full Text] [Related]  

  • 47. Profitable and nonprofitable drugs.
    Van Woert MH
    N Engl J Med; 1978 Apr; 298(16):903-6. PubMed ID: 634333
    [No Abstract]   [Full Text] [Related]  

  • 48. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 49. Controversies in adverse drug reaction reporting.
    Juergens JP
    Am J Hosp Pharm; 1990 Jan; 47(1):76-7. PubMed ID: 2301428
    [No Abstract]   [Full Text] [Related]  

  • 50. Has the FDA Amendments Act of 2007 impaired drug development?
    Franson TR
    Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reporting drug product defects--JCAHO.
    Hoffmann RP
    Hosp Pharm; 1989 Feb; 24(2):143-4. PubMed ID: 10318199
    [No Abstract]   [Full Text] [Related]  

  • 52. The US Food and Drug Administration and probiotics: regulatory categorization.
    Degnan FH
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The FDA at work: cutting-edge science promoting public health.
    Hilts PJ
    FDA Consum; 2006; 40(1):28-35, 39-41. PubMed ID: 16528824
    [No Abstract]   [Full Text] [Related]  

  • 54. US health agencies at odds over trial deaths.
    Macilwain C
    Nature; 1994 Jun; 369(6480):433. PubMed ID: 8202125
    [No Abstract]   [Full Text] [Related]  

  • 55. Postmarketing surveillance for oncology drugs.
    Viale PH; Moore S
    Clin J Oncol Nurs; 2008 Dec; 12(6):877-86. PubMed ID: 19064381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implications for the FDA/Center for Veterinary Medicine (CVM).
    Geyer RE
    J Am Vet Med Assoc; 1993 May; 202(10):1718-23. PubMed ID: 8514592
    [No Abstract]   [Full Text] [Related]  

  • 57. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 58. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM
    Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract]   [Full Text] [Related]  

  • 59. Current FDA policy on use of human-labeled drugs in animals.
    Teske RH
    J Am Vet Med Assoc; 1993 May; 202(10):1632-3;discussion 1634. PubMed ID: 8514570
    [No Abstract]   [Full Text] [Related]  

  • 60. The National Institutes of Health and the Best Pharmaceuticals for Children Act.
    Zajicek A
    Paediatr Drugs; 2009; 11(1):45-7. PubMed ID: 19127953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.